Observational Study of MEK Inhibitor-Based Combination Therapy in Adults with KRAS G12R Mutated Advanced Pancreatic Ductal Adenocarcinoma

What this Trial Is About

This research aims to better understand treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma PDAC whose tumors have a specific KRAS G12R mutation. It focuses on evaluating the safety and effectiveness of different therapies involving mitogen-activated protein kinase kinase inhibitors MEKi combined with other treatments. The study also assesses whether it is feasible to conduct future clinical trials using these combination therapies. The study observes patients receiving one of several treatment approaches therapy without MEKi, therapy combining MEKi with hydroxychloroquine HCQ, therapy combining MEKi with an epidermal growth factor receptor inhibitor EGFRi, or other MEKi-based combination therapies. Patients tumor mutations are confirmed through molecular testing such as next-generation sequencing or circulating tumor DNA panels chosen by their doctors. Treatments are administered as part of the patients standard care, and data is collected both retrospectively and prospectively. Participants provide medical records and undergo molecular profiling to track tumor response, survival rates, and any treatment-related side effects. Researchers analyze these outcomes over time, including the number of patients without disease progression at six months and responses or adverse events over two years. The study continues until 2027 and involves reviewing patient outcomes to guide future therapy strategies and clinical trial planning for this patient group.

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy